About Us


Molecular Targeting Technologies, Inc. (MTTI)

Our Mission: Translating prolonged targeted radiotherapeutics (PTR) into tomorrow's medicine.

Our Targets: supported by published data and ongoing Phase I clinical trials:

Therapeutics:

EBTATE (Lu-177-EB-DOTA-TATE), a prolonged targeted radiotherapeutics for neuroendocrine tumor (NET).

EBRGD (Lu-177-EBRGD), a prolonged targeted radiotherapeutics for glioblastoma multiforme (GBM), and non-small-cell lung cancer (NSCLC).

Diagnostics:

F-18-glucaric acid (a necrosis PET imaging agent) is being developed for early prediction of tumor response to drug treatment.
TDURA (Tc-99m-duramycin), targets cell death in multiple applications including cardiotoxicity, atherosclerotic plaque, systemic inflammatory response syndrome (SIRS) and organ transplant rejection.

*See pipeline page